License deal in oncolytic virotherapies

Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.

Read more

Helena Strigård becomes CEO of Swedenbio

Swedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,

Read more

Teckro Expands Leadership Team

Teckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.

Read more

Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
Read more

Smart bra set to detect breast cancer

A French-Swiss research team is developing a “smart bra” for detecting breast cancer more accessible than through mammography.

Read more

Trilogue put lights on green for Horizon Europe

The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliament’s proposal to increase its budget from €100bn to €120bn.

Read more

GARDP wants five AMR breakers by 2025

GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.

Read more

New CEO at Morphosys

Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.

Read more

Sanifit raise €72.2m to push SNF472 development

Sanifit has bagged €72.2m in Spain’s largest private biotech fundraise.
Read more

Genfit in $228m deal with Terns Pharmaceuticals

Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor  to Terns Pharmaceuticals Inc.
                                                                           

Read more